Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Label, Randomized, Non-Comparative Cohorts Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Next Previous
Search
Trial Profile

A Phase II, Open Label, Randomized, Non-Comparative Cohorts Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
  • Indications Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMperator
  • Sponsors Roche; Roche Farma

    • Most Recent Events

    • 24 Dec 2024 Status changed from recruiting to withdrawn prior to enrolment. (Reason the study was withdrawn: Global desprioritization decision by the sponsor. )
    • 31 Oct 2024 Planned primary completion date changed from 20 Oct 2028 to 30 Nov 2028.
    • 17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top